Cargando...
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
SIMPLE SUMMARY: The CD38-targeting antibody daratumumab mediates its anti-myeloma activities not only through direct effects on tumor cells, but also by its effects on T-cell immunity through depletion of CD38(+) immune suppressor cells. We hypothesized that combining daratumumab with modulators of...
Guardado en:
| Publicado en: | Cancers (Basel) |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7764511/ https://ncbi.nlm.nih.gov/pubmed/33321969 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12123713 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|